Summary
SALES are booming at Britain's two drugs giants. But beneath sparkling sets of figures from AstraZeneca and GlaxoSmithKline lie distinct challenges to ensure that both have a future in rude health.
New drugs are gushing out of GSK's pipeline, and the phone is ringing off the hook with inquiries for its flu vaccines.See the full content of this document
Extract
Clean Bill of Health for the Drugs Giants ; City Focus
Meanwhile, AZ is going shopping to restock its medicine cabinet before competition from cheap copies weakens its blockbuster treatments.
GSK's profits in the last three months rose 27pc to Pounds 2.17bn. AZ shot up 38pc ...See the full content of this document
Sponsored links
